CARVYKTI

This brand name is authorized in Canada, Estonia, France, Croatia, Lithuania, Romania, United States

Active ingredients

The drug CARVYKTI contains one active pharmaceutical ingredient (API):

1 Ciltacabtagene autoleucel UNII 0L1F17908Q - CILTACABTAGENE AUTOLEUCEL

Ciltacabtagene autoleucel is a BCMA-directed, genetically modified autologous T cell immunotherapy, which involves reprogramming a patient’s own T cells with a transgene encoding a chimeric antigen receptor (CAR) that identifies and eliminates cells that express BCMA. BCMA is primarily expressed on the surface of malignant multiple myeloma B-lineage cells, as well as late-stage B cells and plasma cells. Read about Ciltacabtagene autoleucel

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
CARVYKTI Dispersion for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01X	Other antineoplastic agents	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents
Discover more medicines within L01X

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02535270
Country: EE	Ravimiamet	Identifier(s): 1885057, 1885068
Country: FR	Base de données publique des médicaments	Identifier(s): 64743778
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1094945
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W68977001
Country: US	FDA, National Drug Code	Identifier(s): 57894-111